The Effects of DLEU1 Gene Expression in Burkitt Lymphoma (BL): Potential Mechanism of Chemoimmunotherapy Resistance in BL

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 22

PMID 28427156

Citations 21

Authors

Sanghoon Lee

Wen Luo

Tishi Shah

Changhong Yin

Timmy OConnell

Tae-Hoon Chung

Sherrie L Perkins

Rodney R Miles

Janet Ayello

Erin Morris

Lauren Harrison

Carmella van de Ven

Mitchell S Cairo

Affiliations

Soon will be listed here.

Abstract

Following a multivariant analysis we demonstrated that children and adolescents with Burkitt lymphoma (BL) and a 13q14.3 deletion have a significant decrease in event free survival (EFS) despite identical short intensive multi-agent chemotherapy. However, how this deletion in the 13q14.3 region is associated with a significant decrease in EFS in children and adolescents with BL is largely unknown. The gene Deleted in Lymphocytic Leukemia 1 (DLEU1) is located in the region of 13q14.3. Here, we report that DLEU1 expression is implicated in the regulation of BL programmed cell death, cell proliferation, and expression of apoptotic genes in transcription activator-like effector nuclease (TALEN)s-induced DLEU1 knockdown and DLEU1 overexpressing BL cell lines. Furthermore, NSG mice xenografted with DLEU1 knockdown BL cells had significantly shortened survival (p < 0.05 and p < 0.005), whereas those xenografted with DLEU1 overexpressing BL cells had significantly improved survival (p < 0.05 and p < 0.0001), following treatment with rituximab and/or cyclophosphamide. These data suggest that DLEU1 may in part function as a tumor suppressor gene and confer chemoimmunotherapy resistance in children and adolescents with BL.

Citing Articles

binding domain mutations are bad news in Burkitt lymphoma.

Cairo M Haematologica. 2024; 109(9):2775-2777.

PMID: 38634119 PMC: 11367188. DOI: 10.3324/haematol.2024.285213.

Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.

Khanmohammadi S, Fallahtafti P J Cell Mol Med. 2023; 27(14):1928-1946.

PMID: 37246627 PMC: 10339099. DOI: 10.1111/jcmm.17795.

Retracted Article: Long noncoding RNA DLEU1 promotes cell proliferation and migration of Wilms tumor through the miR-300/HOXC8 axis.

Ge W, Wang S RSC Adv. 2022; 9(69):40240-40247.

PMID: 35542655 PMC: 9076220. DOI: 10.1039/c9ra07215b.

Whole-genome-scale identification of novel non-protein-coding RNAs controlling cell proliferation and survival through a functional forward genetics strategy.

Tonge D, Darling D, Farzaneh F, Williams G Sci Rep. 2022; 12(1):182.

PMID: 34997014 PMC: 8741825. DOI: 10.1038/s41598-021-03983-5.

Overexpression of lncRNA DLEU1 in Gastric Cancer Tissues Compared to Adjacent Non-Tumor Tissues.

Ghodrati R, Safaralizadeh R, Dastmalchi N, Hosseinpourfeizi M, Asadi M, Shirmohammadi M J Gastrointest Cancer. 2021; 53(4):990-994.

PMID: 34738190 DOI: 10.1007/s12029-021-00733-8.

References

Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T . The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010; 17(1):28-40. DOI: 10.1016/j.ccr.2009.11.019. View

Goldman S, Smith L, ANDERSON J, Perkins S, Harrison L, Geyer M . Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2012; 27(5):1174-7. PMC: 4539148. DOI: 10.1038/leu.2012.255. View

Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R . Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2006; 109(7):2773-80. PMC: 1852229. DOI: 10.1182/blood-2006-07-036673. View

Liu L, Amy V, Liu G, McKeehan W . Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cells. In Vitro Cell Dev Biol Anim. 2003; 38(10):582-94. PMC: 3225227. DOI: 10.1290/1543-706x(2002)38<582:ncimat>2.0.co;2. View

Poirel H, Cairo M, Heerema N, Swansbury J, Auperin A, Launay E . Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2008; 23(2):323-31. PMC: 2988438. DOI: 10.1038/leu.2008.312. View

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

Chen E, Kwon Y, Lim M, Dube I, Hough M . Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice. Oncogene. 2006; 25(42):5752-63. DOI: 10.1038/sj.onc.1209573. View

Reyon D, Tsai S, Khayter C, Foden J, Sander J, Joung J . FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. 2012; 30(5):460-5. PMC: 3558947. DOI: 10.1038/nbt.2170. View

Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, Dohner K . Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene. 1998; 16(14):1891-7. DOI: 10.1038/sj.onc.1201764. View

10.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

11.

Niazi F, Valadkhan S . Computational analysis of functional long noncoding RNAs reveals lack of peptide-coding capacity and parallels with 3' UTRs. RNA. 2012; 18(4):825-43. PMC: 3312569. DOI: 10.1261/rna.029520.111. View

12.

Gerrard M, Cairo M, Weston C, Auperin A, Pinkerton R, Lambilliote A . Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008; 141(6):840-7. DOI: 10.1111/j.1365-2141.2008.07144.x. View

13.

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

14.

de Weers M, Brouns G, Hinshelwood S, Kinnon C, Schuurman R, Hendriks R . B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem. 1994; 269(39):23857-60. View

15.

Suzuki E, Umezawa K, Bonavida B . Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene. 2007; 26(42):6184-93. DOI: 10.1038/sj.onc.1210448. View

16.

Lee S, Huang H, Niu Y, Tommasino M, Lenoir G, Sylla B . Dok1 expression and mutation in Burkitt's lymphoma cell lines. Cancer Lett. 2005; 245(1-2):44-50. DOI: 10.1016/j.canlet.2005.10.045. View

17.

Nelson M, Perkins S, Dave B, Coccia P, Bridge J, Lyden E . An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol. 2009; 148(4):600-10. PMC: 2921871. DOI: 10.1111/j.1365-2141.2009.07967.x. View

18.

Goldman S, Smith L, Galardy P, Perkins S, Frazer J, Sanger W . Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014; 167(3):394-401. PMC: 4198418. DOI: 10.1111/bjh.13040. View

19.

Young R, Staudt L . Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013; 12(3):229-43. PMC: 7595252. DOI: 10.1038/nrd3937. View

20.

Sander J, Maeder M, Joung J . Engineering designer nucleases with customized cleavage specificities. Curr Protoc Mol Biol. 2011; Chapter 12:Unit12.13. PMC: 3379964. DOI: 10.1002/0471142727.mb1213s96. View